ArticleAmerican journal of cancer research2023

The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.

Longhao Zhang et al.PubMed ↗Full text ↗

No numbers read from the abstract.